DGAP-News: aap Implantate AG / Key word(s): Annual Results
12.03.2019 / 16:44
The issuer is solely responsible for the content of this announcement.
The Management Board of aap Implantate AG (“aap”) continues to consistently pursue the strategy to develop aap into a sustainably growing pure player in trauma and to unlock the inherent value of the promising and innovative product and technology base.
In implementing this strategy new developments and temporal shifts occurred in recent months, which require an evaluation and decision on various issues by Management Board and Supervisory Board. As individual decisions within this upcoming evaluation could have to be considered in the annual and consolidated accounts 2018, the company decided to postpone the publication of the annual financial statements 2018 (HGB) and the consolidated financial statements 2018 (IFRS) to 30 April 2019. aap will report on possible developments within this process again after Management Board and Supervisory Board have jointly taken decisions or terminated the evaluation of the topics by other means.
About aap Implantate AG
For inquiries please contact: aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin; Tel.: +49/30/750 19 – 134; Fax.: +49/30/750 19 – 290; firstname.lastname@example.org
12.03.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||aap Implantate AG|
|Phone:||+49 (0) 30 75 01 90|
|Fax:||+49 (0) 30 75 01 91 11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|